-
公开(公告)号：US20100021476A1
公开(公告)日：2010-01-28
申请号：US12554029
申请日：2009-09-04
申请人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
发明人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
IPC分类号： A61K39/395 , A61P11/06 , A61P17/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
-
52.发明申请公开(公告)号：US20090155899A1
公开(公告)日：2009-06-18
申请号：US12334927
申请日：2008-12-15
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译： 公开了具有改善的药代动力学的修饰的嵌合多肽。 具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。 还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。
-
公开(公告)号：US20090081217A1
公开(公告)日：2009-03-26
申请号：US12102666
申请日：2008-04-14
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
-
54.发明授权Cell culture compositions capable of producing a VEGF-binding fusion polypeptide 有权能产生VEGF结合融合多肽的细胞培养组合物公开(公告)号：US08343737B2
公开(公告)日：2013-01-01
申请号：US13106910
申请日：2011-05-13
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： The present invention provides cell culture compositions capable of producing fusion polypeptides that bind vascular endothelial growth factor (VEGF). The cell culture compositions of the invention comprise cells which contain an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide that binds VEGF. The fusion polypeptides may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.
摘要翻译： 本发明提供能够产生结合血管内皮生长因子（VEGF）的融合多肽的细胞培养组合物。 本发明的细胞培养组合物包含含有包含编码结合VEGF的融合多肽的核酸分子的表达载体的细胞。 融合多肽可以包含具有第一VEGF受体的免疫球蛋白样（Ig）结构域2，第二VEGF受体的Ig结构域3和多聚化成分的VEGF受体组分。
-
55.发明授权公开(公告)号：US08101724B2
公开(公告)日：2012-01-24
申请号：US12877133
申请日：2010-09-08
申请人： Lynn MacDonald , Andrew J. Murphy , Nicholas J. Papadopoulos , Marc R. Morra , Robert R. Salzler , Michael L. LaCroix-Fralish
发明人： Lynn MacDonald , Andrew J. Murphy , Nicholas J. Papadopoulos , Marc R. Morra , Robert R. Salzler , Michael L. LaCroix-Fralish
IPC分类号： C12P21/08 , A61K39/00 , A61K39/395 , C07K16/00
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76
摘要： The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.
摘要翻译： 本发明提供了结合蛋白酶激活受体-2（PAR-2）的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人类PAR-2结合的完全人抗体。 本发明的抗体可用于治疗与一种或多种PAR-2生物活性相关的疾病和病症，包括治疗疼痛病症，炎性病症和胃肠病症。
-
公开(公告)号：US08092802B2
公开(公告)日：2012-01-10
申请号：US12821499
申请日：2010-06-23
申请人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
发明人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
IPC分类号： A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
-
公开(公告)号：US07919593B2
公开(公告)日：2011-04-05
申请号：US12002245
申请日：2007-12-14
IPC分类号： C07K16/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of ≦500 pM, as measured by surface plasmon resonance.
摘要翻译： 分离的人抗体或人抗体的片段，其特异性结合人类δ样配体4（hDll4）并阻断hDll4与Notch受体的结合。 通过表面等离振子共振测量，人抗hDll4抗体或抗体片段以＆nlE; 500pM的亲和力结合hDll4。
-
58.发明申请公开(公告)号：US20110028698A1
公开(公告)日：2011-02-03
申请号：US12885185
申请日：2010-09-17
IPC分类号： C07K16/00
CPC分类号： C07K14/71 , A61K38/00 , C07H21/04 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30 , C12N15/09 , C12N15/10
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译： 公开了具有改善的药代动力学的修饰的嵌合多肽。 具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。 还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。
-
公开(公告)号：US07608693B2
公开(公告)日：2009-10-27
申请号：US12260307
申请日：2008-10-29
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (KD), capable of blocking hIL-4 and hIL-13 activity.
摘要翻译： 以高亲和力（KD）结合能够阻断hIL-4和hIL-13活性的人白细胞介素-4受体α（hIL-4Ralpha）的分离的人抗体或其抗体片段。
-
公开(公告)号：US20090074793A1
公开(公告)日：2009-03-19
申请号：US12260307
申请日：2008-10-29
IPC分类号： A61K39/395 , C07K16/18 , C07H21/00 , C12N15/64 , A61P37/06 , C12N1/21 , C12N5/10 , C12P21/00
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (KD), capable of blocking hIL-4 and hIL-13 activity.
摘要翻译： 以高亲和力（KD）结合能够阻断hIL-4和hIL-13活性的人白细胞介素-4受体α（hIL-4Ralpha）的分离的人抗体或其抗体片段。
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.068 秒)
